SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
Condition: Heart Failure With Preserved Ejection Fraction Interventions: Drug: Empagliflozin + Potassium Chloride; Drug: Empagliflozin + Potassium Nitrate; Drug: Potassium Chloride + Placebo for Empagliflozin Sponsor: University of Pennsylvania Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chloride | Empagliflozin | Jardiance | Klor-Con | Potassium | Potassium Chloride | Research